Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
SESelecta Biosciences, Inc. logo

Selecta Biosciences, Inc. (SELB)

NASDAQ Global Market · Currency in USD
$0.88 ▼ -0.08 (-8.00%)
At close: Nov 13, 4:00 PM ET. Market closed.

Summary

Previous Close
$0.96
Open
$0.89
Day's Range
$0.81 – $0.94
52 Week Range
$0.79 – $1.99
Volume
2,763,021
Avg. Volume
633,492
Market Cap
$135.20M
Beta (5Y Monthly)
0.83
PE Ratio (TTM)
--
EPS (TTM)
-$5.15
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Selecta Biosciences, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
64
CEO
Carsten Brunn

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical firm dedicated to the research and development of innovative nanoparticle immunomodulatory medications aimed at treating and preventing various human ailments. The company's most advanced gene therapy initiative is SEL-302, currently in preclinical development to enhance therapeutic options for methylmalonic acidemia. Among its biologic therapies, SEL-212 is undergoing Phase III clinical trials for the management of chronic refractory gout.

Earnings

DateEst.Actual
Aug 6, 2026–$0.47
Apr 30, 2026–-$1.46
Mar 9, 2026–-$3.47
Nov 2, 2023-$0.07-$0.01Beat
Aug 17, 2023-$0.09-$0.07Beat
May 4, 2023-$0.08-$0.11Miss

Analyst view

Rating: Buy
Buy 91% · Hold 9% · Sell 0%

Get free alerts on SELB and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.